Skip navigation

Office of Research & Sponsored Programs

mary reed scene

Research Integrity & Education

rDNA & Biosafety (IBC)

Institutional Biosafety Committee (IBC)

Federal Guidelines established by the National Institute of Health, require that institutions conducting or sponsoring research using recombinant or synthetic nucleic acid molecules covered by the NIH Guidelines, be responsible for ensuring that the research is conducted in full conformity with the provisions of the NIH Guidelines.

The University of Denver has established an Institutional Biosafety Committee (IBC), charged with oversight responsibilities for all research related activities involving recombinant or synthetic nucleic acid molecules and other biohazardous materials.

The IBC's primary objective is to safeguard protection of personnel, the general public, and the environment. To meet this goal, the IBC imposes requirements for safe laboratory and biological safety practices; reviews and approves policies, procedures, training, programs and facilities pursuant to the safe use of biological agents, other biological materials, and toxins.

The IBC is responsible for reviewing and approving those research and teaching activities conducted by faculty, staff, students, and/or visiting scientists on DU property, that involve the use of biohazardous materials including regulated animal and plant pathogens, biological toxins, and recombinant or synthetic nucleic acid molecules.

The IBC is responsible for:

  1.  Review and approval of the research or teaching activity performed by individual researchers, on a regular and continuing basis.
  2. Independently assess the containment levels of the work, as required by the NIH Guidelines, for all experiments, including those involving whole plants and/or animals, cell cultures, tissues, human-derived materials, biological toxins, infectious agents, and regulated pathogens and pests.
  3. Assess the facilities, procedures, practices, and training and expertise of personnel involved with biohazardous research.
  4. Lower the containment levels for certain experiments in which DNA from Risk Group 2, 3, or 4 or Restricted Agents is cloned into nonpathogenic prokaryotic or lower eukaryotic host-vector systems.
  5. Perform periodic reviews and/or require modifications of recombinant or synthetic nucleic acid molecules and/or biohazardous research and research facilities at DU to ensure compliance with the NIH Guidelines and other government regulations.
  6. Notify the Principal Investigator of the results of the IBC's review and approval.
  7. Adopt emergency plans covering accidental spills and personnel contamination resulting from research using recombinant or synthetic nucleic acid molecules.
  8. Report significant problems with or violations of the NIH Guidelines and any significant research related accidents or illnesses to the appropriate institutional official and when necessary to NIH/OBA.
  9. In cooperation with the Office of Research & Sponsored Programs, suspend or terminate approval of research that is not being conducted in accordance with the IBC's requirements